João Victor Pereira Gonzalez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
João Victor Pereira Gonzalez has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Luciano Falcão
Department of Medicine, Bahiana School of Medicine and Public Health, Salvador, Brazil
6 shared publications - Anderson Matheus Pereira da Silva
Department of Physiology and Pharmacology, Federal University of Pernambuco, Recife, Brazil
3 shared publications - Kenzo Ogasawara Donato
Department of Medicine, Bahiana School of Medicine and Public Health, Salvador, Brazil
3 shared publications - Mariana Letícia de Bastos Maximiano
Federal Fluminense University
3 shared publications - Ocílio Ribeiro Gonçalves
Federal University of Piaui
3 shared publications André Nishizima
Bahiana School of Medicine and Public Health, Brotas, Salvador, Bahia, Brazil
2 shared publications
Latest Publications
- 20 August 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (9) , 2117-2128
Glucagon‐like peptide‐1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta‐analysis
Objectives/Background: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially developed for type 2 diabetes and obesity, have emerged as promising candidates for idiopathic intracranial hypertension (IIH) due to their metabolic and neurophysiological effects. This systematic review and meta‐analysis aims to summarize, synthesize, and quantitatively pool the available evidence on the use of GLP‐1 RAs in patients with IIH, focusing on clinical outcomes. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were searched through December 2025 for randomized trials and cohort studies assessing GLP‐1 RAs in patients with IIH. Risk of bias was assessed by Risk of Bias in Nonrandomized Studies of Interventions and Cochrane Risk of Bias 2.0. Primary outcomes included papilledema, headache burden, refractory IIH, and visual disturbances. Results: Eight studies comprising 13,243 patients met inclusion criteria. GLP‐1 RAs significantly reduced papilledema risk at 3 months (risk ratio [RR], 0.430; 95% confidence interval [CI], 0.281–0.659; I ‐squared statistic [ I 2 ] = 62.5%) and maintained the benefit through 24 months (RR, 0.469; 95% CI, 0.382–0.576; I 2 = 18.0%). Headache frequency was also consistently lower at 3 months (RR, 0.690; 95% CI, 0.557–0.853; I 2 = 71.0%) and at 24 months (RR, 0.796; 95% CI, 0.691–0.916; I 2 = 68.9%), with similar improvements in visual disturbances at 3 months (RR, 0.408; 95% CI, 0.304–0.547; I 2 = 36.0%) and 24 months (RR, 0.433; 95% CI, 0.236–0.796; I 2 = 79.0%), and refractory IIH at 3 months (RR, 0.696; 95% CI, 0.574–0.843; I 2 = 60.0%) and 24 months (RR, 0.808; 95% CI, 0.715–0.908; I 2 = 52.0%) compared to control group. Conclusion: GLP‐1 RAs appear associated with improvements in clinical outcomes in IIH, including reductions in papilledema, headache, and visual symptoms. The current evidence base is dominated by observational studies with moderate to serious risk of confounding, resulting in low‐certainty, hypothesis‐generating evidence. These findings should be interpreted cautiously and primarily serve to inform the design of future well powered randomized controlled trials.
- 20 August 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (9) , 2117-2128
Glucagon‐like peptide‐1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta‐analysis
Objectives/Background: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially developed for type 2 diabetes and obesity, have emerged as promising candidates for idiopathic intracranial hypertension (IIH) due to their metabolic and neurophysiological effects. This systematic review and meta‐analysis aims to summarize, synthesize, and quantitatively pool the available evidence on the use of GLP‐1 RAs in patients with IIH, focusing on clinical outcomes. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were searched through December 2025 for randomized trials and cohort studies assessing GLP‐1 RAs in patients with IIH. Risk of bias was assessed by Risk of Bias in Nonrandomized Studies of Interventions and Cochrane Risk of Bias 2.0. Primary outcomes included papilledema, headache burden, refractory IIH, and visual disturbances. Results: Eight studies comprising 13,243 patients met inclusion criteria. GLP‐1 RAs significantly reduced papilledema risk at 3 months (risk ratio [RR], 0.430; 95% confidence interval [CI], 0.281–0.659; I ‐squared statistic [ I 2 ] = 62.5%) and maintained the benefit through 24 months (RR, 0.469; 95% CI, 0.382–0.576; I 2 = 18.0%). Headache frequency was also consistently lower at 3 months (RR, 0.690; 95% CI, 0.557–0.853; I 2 = 71.0%) and at 24 months (RR, 0.796; 95% CI, 0.691–0.916; I 2 = 68.9%), with similar improvements in visual disturbances at 3 months (RR, 0.408; 95% CI, 0.304–0.547; I 2 = 36.0%) and 24 months (RR, 0.433; 95% CI, 0.236–0.796; I 2 = 79.0%), and refractory IIH at 3 months (RR, 0.696; 95% CI, 0.574–0.843; I 2 = 60.0%) and 24 months (RR, 0.808; 95% CI, 0.715–0.908; I 2 = 52.0%) compared to control group. Conclusion: GLP‐1 RAs appear associated with improvements in clinical outcomes in IIH, including reductions in papilledema, headache, and visual symptoms. The current evidence base is dominated by observational studies with moderate to serious risk of confounding, resulting in low‐certainty, hypothesis‐generating evidence. These findings should be interpreted cautiously and primarily serve to inform the design of future well powered randomized controlled trials.
- 17 August 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
In‐Office Tympanostomy Tube Placement in Awake Pediatric Patients: A Meta‐analysis of Proportions
Objective: To evaluate the feasibility, effectiveness, and safety of in‐office tympanostomy tube placement (TTP) performed in awake pediatric patients without general anesthesia. Data Sources: We searched PubMed, Embase, Web of Science, and the Cochrane Library from inception through March 20, 2025. Review Methods: We screened the abstracts of potentially eligible studies and subsequently assessed the full‐text reports of those deemed relevant in detail. The study adhered to the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines. Study quality and risk of bias were assessed using the ROBINS‐I tool for non‐randomized studies and the AXIS tool for the single cross‐sectional study. Meta‐analyses of proportions were conducted in R using the meta package. Results: Eleven studies met inclusion criteria. Office‐based TTP demonstrated a high pooled procedural success rate of 97% (95% CI, 0.89‐0.99; P < .01; I 2 = 86.4%). Pain levels were low, with a mean Face, Legs, Activity, Cry, and Consolability (FLACC) score of 1.26 (95% CI, 1.10‐1.45; I 2 = 0%), consistent with mild discomfort. Parental satisfaction was uniformly high at 95% (95% CI, 0.92‐0.97; I 2 = 0%). Adverse events were infrequent, generally mild, and comparable in severity to those reported for operating‐room tympanostomy under general anesthesia. Conclusion: Office‐based TTP in awake pediatric patients appears to be a safe, effective, and well‐tolerated alternative to operative tympanostomy under general anesthesia, offering high success rates, minimal discomfort, and strong caregiver acceptance while reducing anesthesia exposure and healthcare costs.
- 17 August 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
In‐Office Tympanostomy Tube Placement in Awake Pediatric Patients: A Meta‐analysis of Proportions
Objective: To evaluate the feasibility, effectiveness, and safety of in‐office tympanostomy tube placement (TTP) performed in awake pediatric patients without general anesthesia. Data Sources: We searched PubMed, Embase, Web of Science, and the Cochrane Library from inception through March 20, 2025. Review Methods: We screened the abstracts of potentially eligible studies and subsequently assessed the full‐text reports of those deemed relevant in detail. The study adhered to the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines. Study quality and risk of bias were assessed using the ROBINS‐I tool for non‐randomized studies and the AXIS tool for the single cross‐sectional study. Meta‐analyses of proportions were conducted in R using the meta package. Results: Eleven studies met inclusion criteria. Office‐based TTP demonstrated a high pooled procedural success rate of 97% (95% CI, 0.89‐0.99; P < .01; I 2 = 86.4%). Pain levels were low, with a mean Face, Legs, Activity, Cry, and Consolability (FLACC) score of 1.26 (95% CI, 1.10‐1.45; I 2 = 0%), consistent with mild discomfort. Parental satisfaction was uniformly high at 95% (95% CI, 0.92‐0.97; I 2 = 0%). Adverse events were infrequent, generally mild, and comparable in severity to those reported for operating‐room tympanostomy under general anesthesia. Conclusion: Office‐based TTP in awake pediatric patients appears to be a safe, effective, and well‐tolerated alternative to operative tympanostomy under general anesthesia, offering high success rates, minimal discomfort, and strong caregiver acceptance while reducing anesthesia exposure and healthcare costs.
- Open Access
- 11 August 2026
- Published by Elsevier in North American Spine Society Journal (NASSJ)
- Vol. 28
Do glucagon-like peptide-1 receptor agonists influence cervical fusion outcomes? A systematic review and meta-analysis
- 11 August 2026
- Published by Elsevier in North American Spine Society Journal (NASSJ)
- Vol. 28
Open AccessDo glucagon-like peptide-1 receptor agonists influence cervical fusion outcomes? A systematic review and meta-analysis
- Open Access
- 16 July 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (8) , 637
Association between circadian rhythm disturbances and cognitive decline in the elderly: a systematic review
Background: Circadian rhythm dysregulation may contribute to sleep-wake disorders and cognitive impairment. In the elderly, circadian abnormalities have been observed in Mild Cognitive Impairment (MCI), suggesting a possible association between neurocognitive deficits and circadian dysfunctions. Objective: To analyze the association between circadian rhythm disturbances and cognitive decline in the population aged ≥ 60 years. Methods: This systematic review included studies evaluating the association between circadian rhythm disturbances and cognitive decline in elderly individuals aged 60 years or older, with self-reported or objectively measured sleep data and cognitive assessment via questionnaires. Studies tracking progression from MCI to Alzheimer’s disease (AD) were retained, as they capture circadian changes across the MCI-to-dementia continuum. Studies that evaluated other sleep disorders and/or other conditions of cognitive impairment exclusively or that did not specify the mean age of the participants were excluded. Results: Ten studies were included, totaling 5,731 participants (5 , 707 eligible for analysis ). Circadian exposures were organized into three domains: (1) actigraphic rest-activity rhythm metrics (amplitude, robustness, interdaily stability, intradaily variability, and acrophase); (2) sleep quality and architecture parameters (efficiency, fragmentation, latency, WASO, and melatonin timing); and (3) circadian-disrupting lifestyle exposures (rotating night shift work). Across these domains, circadian dysregulation was consistently associated with a higher risk of development or progression of MCI and dementia. Conclusion: Circadian and sleep disturbances negatively impact cognitive health in the elderly, reinforcing the need for further research on this association and its public health implications.
- 16 July 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (8) , 637
Open AccessAssociation between circadian rhythm disturbances and cognitive decline in the elderly: a systematic review
Background: Circadian rhythm dysregulation may contribute to sleep-wake disorders and cognitive impairment. In the elderly, circadian abnormalities have been observed in Mild Cognitive Impairment (MCI), suggesting a possible association between neurocognitive deficits and circadian dysfunctions. Objective: To analyze the association between circadian rhythm disturbances and cognitive decline in the population aged ≥ 60 years. Methods: This systematic review included studies evaluating the association between circadian rhythm disturbances and cognitive decline in elderly individuals aged 60 years or older, with self-reported or objectively measured sleep data and cognitive assessment via questionnaires. Studies tracking progression from MCI to Alzheimer’s disease (AD) were retained, as they capture circadian changes across the MCI-to-dementia continuum. Studies that evaluated other sleep disorders and/or other conditions of cognitive impairment exclusively or that did not specify the mean age of the participants were excluded. Results: Ten studies were included, totaling 5,731 participants (5 , 707 eligible for analysis ). Circadian exposures were organized into three domains: (1) actigraphic rest-activity rhythm metrics (amplitude, robustness, interdaily stability, intradaily variability, and acrophase); (2) sleep quality and architecture parameters (efficiency, fragmentation, latency, WASO, and melatonin timing); and (3) circadian-disrupting lifestyle exposures (rotating night shift work). Across these domains, circadian dysregulation was consistently associated with a higher risk of development or progression of MCI and dementia. Conclusion: Circadian and sleep disturbances negatively impact cognitive health in the elderly, reinforcing the need for further research on this association and its public health implications.
- 9 March 2026
- Published by Springer Nature in Clinical Neuroradiology
- Vol. 36 (3) , 1-12
Diagnostic Accuracy of Machine Learning Models in Predicting Functional Outcome of Thrombectomy for Acute Posterior Circulation Artery Occlusion: a Systematic Review and Meta-Analysis
Background Mechanical thrombectomy (MT) is the standard treatment for acute posterior circulation artery occlusion (PCAO), but predicting outcomes remains challenging. Existing prognostic models combine clinical, imaging, and procedural variables but show inconsistent performance. Our objective is to evaluate the diagnostic accuracy of Machine Learning (ML) models in predicting favorable functional outcomes of thrombectomy for acute PCAO. Methods We conducted a systematic review and bivariate diagnostic meta-analysis of PubMed, Embase, and Web of Science. Eligible studies evaluated ML predicting favorable outcomes (Modified Rankin Scale of 0 to 3 at hospital discharge or at 90 days) after MT for PCAO. Pooled sensitivity, specificity, and area under the summary receiver operating characteristic curve (AUC) were calculated with a bivariate random-effects model. Results Five studies including 1739 patients met inclusion criteria. Pooled sensitivity was 78% (95% CI: 59–89%; I2 = 89.29%) and specificity was 80% (95% CI: 74–85%; I2 = 46.06%) for a favorable outcome. The Summary Receiver Operating Characteristic (SROC) curve yielded an AUC of 83% (95% CI: 80–86%). Subgroup analyses revealed that studies including patients with successful reperfusion (mTICI ≥ 2b) had significantly lower sensitivity and specificity. Random forest-based models achieved greater specificity, and multicenter studies demonstrated inferior specificity compared to single-center designs. Conclusions ML models demonstrate good diagnostic accuracy in predicting functional outcomes after thrombectomy for acute PCAO. Integration of these models into clinical practice may support individualized decision-making and resource allocation, although prospective validation and improved reporting are needed before routine implementation.
- 9 March 2026
- Published by Springer Nature in Clinical Neuroradiology
- Vol. 36 (3) , 1-12
Diagnostic Accuracy of Machine Learning Models in Predicting Functional Outcome of Thrombectomy for Acute Posterior Circulation Artery Occlusion: a Systematic Review and Meta-Analysis
Background Mechanical thrombectomy (MT) is the standard treatment for acute posterior circulation artery occlusion (PCAO), but predicting outcomes remains challenging. Existing prognostic models combine clinical, imaging, and procedural variables but show inconsistent performance. Our objective is to evaluate the diagnostic accuracy of Machine Learning (ML) models in predicting favorable functional outcomes of thrombectomy for acute PCAO. Methods We conducted a systematic review and bivariate diagnostic meta-analysis of PubMed, Embase, and Web of Science. Eligible studies evaluated ML predicting favorable outcomes (Modified Rankin Scale of 0 to 3 at hospital discharge or at 90 days) after MT for PCAO. Pooled sensitivity, specificity, and area under the summary receiver operating characteristic curve (AUC) were calculated with a bivariate random-effects model. Results Five studies including 1739 patients met inclusion criteria. Pooled sensitivity was 78% (95% CI: 59–89%; I2 = 89.29%) and specificity was 80% (95% CI: 74–85%; I2 = 46.06%) for a favorable outcome. The Summary Receiver Operating Characteristic (SROC) curve yielded an AUC of 83% (95% CI: 80–86%). Subgroup analyses revealed that studies including patients with successful reperfusion (mTICI ≥ 2b) had significantly lower sensitivity and specificity. Random forest-based models achieved greater specificity, and multicenter studies demonstrated inferior specificity compared to single-center designs. Conclusions ML models demonstrate good diagnostic accuracy in predicting functional outcomes after thrombectomy for acute PCAO. Integration of these models into clinical practice may support individualized decision-making and resource allocation, although prospective validation and improved reporting are needed before routine implementation.
- 22 February 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-12
Efficacy and safety of modafinil in post-stroke fatigue: a systematic review and meta-analysis
Post-stroke fatigue (PSF) is a common and disabling condition that limits rehabilitation and quality of life, yet no pharmacological treatment is well established. Modafinil, a wakefulness-promoting agent, has been proposed as a potential therapy. This systematic review and meta-analysis evaluated its efficacy and safety in PSF. Four studies (two RCTs, two observational) comprising 1001 met inclusion criteria. Modafinil did not significantly improve overall fatigue severity on the MFI or FSS. A domain-specific benefit was observed for mental fatigue (MD -2.51; p = 0.0005), with no significant effects on physical, general, or activity-related fatigue. No improvements were found in quality of life (SSQoL) or cognition (MoCA). Modafinil was generally well tolerated with few mild adverse events. Current evidence does not support modafinil as a routine treatment for PSF. Its effect on mental fatigue is of very low certainty, limiting the strength of this finding. Clinicians should interpret these findings cautiously, and use modafinil only on a case-by-case basis. Larger, high-quality trials with standardized fatigue measures are needed to identify responders and clarify its clinical role.
- 22 February 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-12
Efficacy and safety of modafinil in post-stroke fatigue: a systematic review and meta-analysis
Post-stroke fatigue (PSF) is a common and disabling condition that limits rehabilitation and quality of life, yet no pharmacological treatment is well established. Modafinil, a wakefulness-promoting agent, has been proposed as a potential therapy. This systematic review and meta-analysis evaluated its efficacy and safety in PSF. Four studies (two RCTs, two observational) comprising 1001 met inclusion criteria. Modafinil did not significantly improve overall fatigue severity on the MFI or FSS. A domain-specific benefit was observed for mental fatigue (MD -2.51; p = 0.0005), with no significant effects on physical, general, or activity-related fatigue. No improvements were found in quality of life (SSQoL) or cognition (MoCA). Modafinil was generally well tolerated with few mild adverse events. Current evidence does not support modafinil as a routine treatment for PSF. Its effect on mental fatigue is of very low certainty, limiting the strength of this finding. Clinicians should interpret these findings cautiously, and use modafinil only on a case-by-case basis. Larger, high-quality trials with standardized fatigue measures are needed to identify responders and clarify its clinical role.
- 14 February 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-14
Dual antiplatelet therapy pretreatment in patients undergoing intravenous thrombolysis for acute ischemic stroke: a systematic review and meta-analysis of 296,854 patients
Wea im to evaluate the impact of Dual Antiplatelet Therapy (DAPT) pretreatment on outcomes in patients with Acute Ischemic Stroke (AIS) undergoing intravenous thrombolysis (IVT). A systematic search was conducted from inception to January 2025. Eligible studies included randomized and observational cohorts comparing AIS patients with and without DAPT pretreatment who underwent IVT. Primary outcome was favorable functional outcome at 90 days (mRS 0-1). Secondary outcomes included mRS 0-2, mRS 3-6, in-hospital and 90-day mortality, and symptomatic intracranial hemorrhage (sICH) defined by SITS-MOST, ECASS II, and NINDS criteria. Risk of bias was assessed using the ROBINS-I tool, and meta-analyses were performed with random-effects models. Eight studies including 296,854 patients (61,925 with DAPT and 234,929 without DAPT) were analyzed. DAPT pretreatment was not associated with favorable functional outcome (mRS 0-1; OR: 1.03; 95% CI: 0.92-1.16; p = 0.57; I2 = 0%), in-hospital mortality (OR: 1.00; 95% CI: 1.00-1.00; I2 = 0%), or 90-day mortality (OR: 1.49; 95% CI: 0.99-2.25; p = 0.06; I2 = 52%). No significant increase in sICH was observed using SITS-MOST (I2 = 64%) or ECASS II (I2 = 63%), whereas sICH defined by NINDS was increased (OR: 1.31; 95% CI: 1.19-1.44; p < 0.01; I2 = 48%), corresponding to a 1% absolute risk increase (RD: 0.01; I2 = 0%). Prestroke DAPT was not associated with favorable functional outcome or reduced mortality after IVT and was associated with a higher risk of sICH when defined by NINDS criteria, with a 1% absolute risk increase.
- 14 February 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-14
Dual antiplatelet therapy pretreatment in patients undergoing intravenous thrombolysis for acute ischemic stroke: a systematic review and meta-analysis of 296,854 patients
Wea im to evaluate the impact of Dual Antiplatelet Therapy (DAPT) pretreatment on outcomes in patients with Acute Ischemic Stroke (AIS) undergoing intravenous thrombolysis (IVT). A systematic search was conducted from inception to January 2025. Eligible studies included randomized and observational cohorts comparing AIS patients with and without DAPT pretreatment who underwent IVT. Primary outcome was favorable functional outcome at 90 days (mRS 0-1). Secondary outcomes included mRS 0-2, mRS 3-6, in-hospital and 90-day mortality, and symptomatic intracranial hemorrhage (sICH) defined by SITS-MOST, ECASS II, and NINDS criteria. Risk of bias was assessed using the ROBINS-I tool, and meta-analyses were performed with random-effects models. Eight studies including 296,854 patients (61,925 with DAPT and 234,929 without DAPT) were analyzed. DAPT pretreatment was not associated with favorable functional outcome (mRS 0-1; OR: 1.03; 95% CI: 0.92-1.16; p = 0.57; I2 = 0%), in-hospital mortality (OR: 1.00; 95% CI: 1.00-1.00; I2 = 0%), or 90-day mortality (OR: 1.49; 95% CI: 0.99-2.25; p = 0.06; I2 = 52%). No significant increase in sICH was observed using SITS-MOST (I2 = 64%) or ECASS II (I2 = 63%), whereas sICH defined by NINDS was increased (OR: 1.31; 95% CI: 1.19-1.44; p < 0.01; I2 = 48%), corresponding to a 1% absolute risk increase (RD: 0.01; I2 = 0%). Prestroke DAPT was not associated with favorable functional outcome or reduced mortality after IVT and was associated with a higher risk of sICH when defined by NINDS criteria, with a 1% absolute risk increase.
- 17 March 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 252, 108847
Assessing Glibenclamide’s efficacy on functional recovery in aneurysmal subarachnoid hemorrhage: A meta-analysis of randomized controlled trials
- 17 March 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 252, 108847
Assessing Glibenclamide’s efficacy on functional recovery in aneurysmal subarachnoid hemorrhage: A meta-analysis of randomized controlled trials